Skip to content
All Podcasts – Lifestyle
Author:
Intellia Therapeutics, Inc.
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
June 13, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
June 1, 2026
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
May 11, 2026
Intellia Therapeutics to Participate in Upcoming Investor Conferences
May 5, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
April 29, 2026
Intellia Announces Proposed Public Offering of Common Stock
April 27, 2026
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
April 27, 2026
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
April 27, 2026
1
2
Next Page
→